Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans

United States Special Operations Forces Veterans (SOFV) frequently face a combination of combat-related trauma, traumatic brain injury (TBI), and alcohol misuse. Traditional treatments for these co-occurring conditions often suffer from high dropout rates and limited efficacy. This study evaluated the prospective outcomes of a three-day, naturalistic clinical program in Mexico that utilized combined ibogaine and 5-MeO-DMT-assisted therapy. Researchers tracked 45 veterans who met criteria for risky alcohol use at baseline, collecting data at pre-treatment and at 1-, 3-, and 6-month follow-up intervals to assess changes in alcohol consumption, PTSD symptoms, and cognitive functioning.

The study observed a significant and robust reduction in alcohol misuse across the sample, with improvements appearing by the 1-month mark and remaining stable through the 6-month follow-up. Participants who were classified as treatment responders—those who achieved abstinence or non-risky drinking levels—showed significantly greater improvements in PTSD symptom severity and cognitive functioning compared to non-responders. While the overall cohort experienced meaningful clinical benefits, approximately 53% of the participants were still classified as risky drinkers at the 6-month follow-up, suggesting that while the treatment is promising, it does not achieve universal success.

This research highlights the potential of psychedelic-assisted therapy as a transdiagnostic intervention for veterans who have not responded to conventional mental health treatments. Given the high rates of suicide and substance misuse within the SOFV population, the ability of this intervention to simultaneously address trauma, cognitive deficits, and alcohol misuse is clinically significant. The findings provide a foundation for future, more rigorous randomized controlled trials to determine the specific therapeutic mechanisms and long-term safety of these substances in this high-risk population.